Details of Drug-Drug Interaction
| Drug General Information (ID: DDI4RCP0WL) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Sargramostim | Drug Info | Tisagenlecleucel | Drug Info | |||||
| Drug Type | Protein/peptide | Autologous cell transplant | |||||||
| Therapeutic Class | Colony Stimulating Factors | Antineoplastics | |||||||
| Mechanism of Sargramostim-Tisagenlecleucel Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Sargramostim | Tisagenlecleucel | |||||||
| Mechanism | Interfere with the pharmacologic effects of tisagenlecleucel | Tisagenlecleucel | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Pharmacodynamics | ||||||||
| Factor Description | Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Hematopoietic growth factors, particularly granulocyte-macrophage colony-stimulating factor (GM-CSF), are not recommended during the first 3 weeks following tisagenlecleucel administration or until cytokine release syndrome (CRS) has resolved. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Kymriah (tisagenlecleucel). Novartis Pharmaceuticals, East Hanover, NJ. | ||||||||||||||||||